SCHEMBL12015440

SCHEMBL12015440

CCc1nc2c(cc1Oc1cccc(C)c1)c(OCC(F)(F)F)c(C(=O)NC1CCN(C(=O)CO)CC1)n2C

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ SMO Q99835 1/20 0.50
▸ LMNA P02545 2/20 0.37
▸ GLA P06280 1/20 0.37
▸ HSD17B10 Q99714 1/20 0.37
▸ CTDSP1 Q9GZU7 1/20 0.37
▸ ALDH1A1 P00352 2/20 0.36
▸ HPGD P15428 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ EPHX2 P34913 2/20 0.35
▸ FAAH O00519 1/20 0.35
▸ CYP2D6 P10635 1/20 0.35
▸ CYP2C19 P33261 1/20 0.35
▸ NPSR1 Q6W5P4 1/20 0.35
▸ KDM4E B2RXH2 1/20 0.34
▸ DRD2 P14416 1/20 0.34
▸ DRD3 P35462 1/20 0.34
▸ PPARG P37231 1/20 0.34
▸ NR2E3 Q9Y5X4 1/20 0.34
▸ NCOR2 Q9Y618 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10002785 0.93 SMO (0.50) SMOHSD17B10ALDH1A1HPGDSMN1; SMN2
SCHEMBL12015435 0.87 SMO (0.51) SMOLMNAGLAHSD17B10CTDSP1
SCHEMBL10003233 0.84 SMO (0.52) SMOALDH1A1HPGDSMN1; SMN2EPHX2
SCHEMBL10003135 0.84 SMO (0.52) SMOLMNAHSD17B10ALDH1A1HPGD
SCHEMBL10004015 0.84 SMO (0.57) SMOALDH1A1HPGDSMN1; SMN2EPHX2
SCHEMBL10003712 0.83 SMO (0.49) SMOHSD17B10ALDH1A1HPGDSMN1; SMN2
SCHEMBL10002860 0.82 SMO (0.56) SMOALDH1A1SMN1; SMN2EPHX2DRD2
SCHEMBL10003412 0.82 SMO (0.51) SMOALDH1A1HPGDSMN1; SMN2EPHX2
SCHEMBL10002829 0.82 SMO (0.53) SMO
SCHEMBL10003708 0.82 SMO (0.53) SMOALDH1A1HPGDSMN1; SMN2EPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8486965-B2 Pyrrolo[2,3-b]pyridine derivative and use thereof for treatment of cancer TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-07-16 — — US disclosed
US-20120220569-A1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-08-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120220569-A1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF SMO, GLI1, SHH SMO 1/4885LMNA 4452/4885GLA 1898/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback